Hyperglycemia induced by dexamethasone in metastatic renal cell carcinoma during medication review with follow up. A clinical Case

Authors

  • Alfonso Pereira-Céspedes Universidad de Costa Rica, Facultad de Farmacia, Instituto de Investigaciones Farmacéuticas, Centro Nacional de Información de Medicamentos https://orcid.org/0000-0003-1539-3305

DOI:

https://doi.org/10.60103/phc.v27.e863

Keywords:

kidney neoplasm; dexamethasone; hyperglycemia

Abstract

A case of dexamethasone-induced hyperglycemia in metastatic renal cell carcinoma is presented, identified during the Pharmacotherapeutic Follow-up Service using the Dáder Method provided at the pharmacy. Three negative outcomes associated with medication were identified during follow-up: two related to non-quantitative safety and one to quantitative ineffectiveness. The importance of collaborative work between the pharmacist and physician to improve clinical outcomes is highlighted, as well as the need for close monitoring of capillary blood glucose levels during dexamethasone therapy.

Downloads

Download data is not yet available.

Author Biography

Alfonso Pereira-Céspedes, Universidad de Costa Rica, Facultad de Farmacia, Instituto de Investigaciones Farmacéuticas, Centro Nacional de Información de Medicamentos

Doctor en Farmacia, Universidad de Granada.

Máster en Atención Farmacéutica, Universidad de Costa Rica. 

Licenciado y Doctorado profesional en Farmacia, Universidad de Costa Rica.

Profesor Adjunto. Departamento de Atención Farmacéutica y Farmacia Clínica (Facultad de Farmacia, Universidad de Costa Rica).

Investigador. Instituto de Investigaciones Farmacéuticas (INIFAR), Universidad de Costa Rica.

Farmacéutico. Centro Nacional de Información de Medicamentos (CIMED), INIFAR.

References

Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, et al. Renal cell carcinoma: An overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022 Jun 20;39(3):2022.

Choueiri TK, Hessel C, Halabi S, Sanford B, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 May; 94:115–125. doi: https://doi.org/10.1016/j.ejca.2018.02.012

Ryken TC, McDermott M, Robinson PD, Ammirati M, et al. The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan;96(1):103–114. doi: https://doi.org/10.1007/s11060-009-0057-4

Brooks D, Schulman-Rosenbaum R, Griff M, Lester J, et al. Glucocorticoid-induced hyperglycemia including dexamethasone-associated hyperglycemia in COVID-19 infection: A systematic review. Endocr Pract. 2022 Nov;28(11):1166–1177. doi: https://doi.org/10.1016/j.eprac.2022.07.014

Holle LM, Puri S, Clement JM. Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice. J Oncol Pharm Pract. 2016 Jun;22(3):511–516. doi: https://doi.org/10.1177/1078155215581524

Faus-Dáder MJ, Amariles-Muñoz P, Martínez-Martínez F. Atención Farmacéutica Servicios orientados al paciente. 2 ed. Granada: Editorial Técnica AVICAM; 2022. 453 p.

Published

2025-09-02

How to Cite

Pereira-Céspedes, A. (2025). Hyperglycemia induced by dexamethasone in metastatic renal cell carcinoma during medication review with follow up. A clinical Case. Pharmaceutical Care España, 27. https://doi.org/10.60103/phc.v27.e863

Issue

Section

Casos clínicos